Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 1101-1104

  Leahey, A M ^a,b   Bunin, N J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Hepatic VOD; Pediatric BMT; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; BILIRUBIN; HEPARIN;

ADOLESCENT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; LIVER VEIN OBSTRUCTION; MALE; PRIORITY JOURNAL; WEIGHT GAIN;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HEMORRHAGE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; MALE; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030037141     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 10: 1562-1568.
2. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
3. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549-558.
4. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-2840.
5. Bearman SI, Hinds MS, Wolford JL et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407-411.
6. 2 formation. New Engl J Med 1988, 319: 689-698.
7. Bearman SI, Shen DD, Hinds MS et al. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724-730.
8. Bovill EG, Terrin MC, Stump DC et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. Ann Int Med 1991; 115: 265-265.
9. Baglin TP, Harper P, Marcus PE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator. Bone Marrow Transplant 1990; 5: 439-441.
10. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462.
11. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
12. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Int Med 1993; 118: 255-267.
13. Yu LC, Malkani I, Regueria O et al. Recombinant tissue plasminogen activator (rtPA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994; 46: 194-198.
14. Laporte J, Lesage S, Tilleul P et al. Alteplase for hepatic veno-occlusive disease complicating bone marrow transplantation. Lancet 1992; 339: 1057.
15. Rosti G, Bandini G, Belardinelli A et al. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. Lancet 1992; 339: 1481-1482.
16. Ringden O, Wennberg L, Ericzon BG et al. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. Lancet 1992; 340: 546-547.
17. Otheo de Tejada E, Maldonado MS, Camarero C, Munoz A. Fatal hemorrhage after recombinant tissue plasminogen activator therapy for hepatic veno-occlussive disease complicating autologous BMT. Bone Marrow Transplant 1994; 14: 176-177.
18. Rapold HJ, Lu HR, Zaomin W et al. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator. Blood 1991; 77: 1020-1024.
19. Bearman SI, Anderson GL, Mori M et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736.
20. Frickhofen N, Wiesheth M, Jainta C et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998-2004.